Optimal Use of Bispecific Antibodies for the Treatment of Diffuse Large B-Cell Lymphoma in Canada
CAR-T cell therapy has significantly improved outcomes for patients with relapsed or Cutlery Basket refractory (R/R) diffuse large B-cell lymphoma (DLBCL), but challenges such as limited resources, manufacturing timelines, and notable toxicities persist.Bispecific antibodies (BsAbs), including glofitamab and epcoritamab, have demonstrated promising